Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT02608099

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02608099
Other papers using this trial's data
  • A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial JACC. Clinical electrophysiology, 2018-05 DOI, PubMed 29798783

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02608099. Randomized; no masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-04 (actual). Results posted on 2020-03-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
Acronym
AEIOU
Intervention (Drug)
Interrupted apixaban
Intervention (Drug)
Uninterrupted apixaban
Lead sponsor
Baim Institute for Clinical Research (class: other)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct02608099
Content hash
7eae9e25902697923b36ffafab009163b0d49db0584bb8b64230682848e70f68